Aduro biotech and Merck expand collaboration to evaluate combination of CRS-207 with KEYTRUDA
Aduro Biotech announced the expansion of its clinical collaboration with Merck to include an additional Phase 2 clinical trial to evaluate the combination of CRS-207, Aduro’s LADD…
Read More...
Read More...
